Similar articles

• EORTC protocol 30761: a randomized study of non-metastatic and metastatic prostatic cancer treated by cyproterone acetate versus diethylstilbestrol and medroxyprogesterone acetate. European Organization for Research on Treatment of Cancer Urological Group.

  Pavone-Macaluso M, Schröder FH, de Voogt HJ, Viggiano G, Barasolo E, Lardennois B, de Pauw M, Sylvester R, Smith PH, Suciu S. Pavone-Macaluso M, et al. Prog Clin Biol Res. 1989;303:111-6. Prog Clin Biol Res. 1989. PMID: 2528735 Clinical Trial. No abstract available.
• [Therapy of virginal prostatic cancer with cyproterone acetate].

  Maier U. Maier U. Z Urol Nephrol. 1985 Apr;78(4):181-7. Z Urol Nephrol. 1985. PMID: 3160180 German.
• Lessons from phase III-trials on the hormonal treatment of prostatic cancer. I: Results of EORTC-trials 30761 and 30762.

  de Voogt HJ, Pavone-Macaluso M, Smith PH, de Pauw M, Suciu S. de Voogt HJ, et al. Prog Clin Biol Res. 1988;260:111-7. Prog Clin Biol Res. 1988. PMID: 2966403 Clinical Trial. No abstract available.
• Initiation of LHRH monotherapy for prostate cancer.

  Milsted RA. Milsted RA. Prog Clin Biol Res. 1989;303:69-74. Prog Clin Biol Res. 1989. PMID: 2528742 Review. No abstract available.
• Cyproterone acetate in the management of prostatic cancer.

  Tunn UW. Tunn UW. Prog Clin Biol Res. 1989;303:105-10. Prog Clin Biol Res. 1989. PMID: 2528734 Review. No abstract available.